Case Reports of Precision Medicine in Oncology

A special issue of Reports (ISSN 2571-841X).

Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 1735

Special Issue Editor


E-Mail Website
Guest Editor
1. Paediatric Oncology Unit, Astrid Lindgren’s Children Hospital, SE-171 64 Solna, Sweden
2. Department of Women’s and Children’s Health, Karolinska Institutet, SE-171 77 Stockholm, Sweden
Interests: paediatric haematology and oncology

Special Issue Information

Dear Colleagues,

During the last decade, precision oncology has taken several leaps forward and can now be implemented into clinical management of high-risk pediatric cancer at diagnosis and at relapse. The introduction of whole genome and transcriptomic sequencing have enabled for the identification of clinically targeted treatments, including molecular alteration in several oncogenic signaling pathways. However, these advances have influenced a minority of patients, with the long-term efficacy and toxicity of these novel agents still being relatively unknown.

In this Special Issue, we encourage submissions that include case reports that cover the novel aspects of the following topics:

  • Advances in precision oncology diagnostics and therapeutics;
  • Use of liquid biopsy from plasma or cerebrospinal liquid to inform patient-specific management at diagnosis, relapse or in case of refractory disease;
  • Combination of targeted therapy with conventional chemo-radiotherapy;
  • Case reports where rare unexpected side effects of targeted therapy— including immune therapy—have occurred;
  • Utilization of other techniques to classify and direct therapy, such as proteomics or metabolomics in pediatric precision oncology.

Dr. Tomas Sjöberg Bexelius
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • oncology
  • targeted therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

7 pages, 1917 KiB  
Case Report
Waldenstrom Macroglobulinemia Recurrence with Bing–Neel Syndrome Presentation
by Raffaella Capasso, Miriam Buonincontro, Ferdinando Caranci and Antonio Pinto
Reports 2024, 7(2), 34; https://doi.org/10.3390/reports7020034 - 7 May 2024
Viewed by 1310
Abstract
Bing–Neel syndrome (BNS) is a rare condition that may occur in patients with Waldenstrom macroglobulinemia (WM) and is caused by lymphoplasmacytic infiltration into the central nervous system. BNS is an extramedullary manifestation of WM which may present with various neurological signs and symptoms [...] Read more.
Bing–Neel syndrome (BNS) is a rare condition that may occur in patients with Waldenstrom macroglobulinemia (WM) and is caused by lymphoplasmacytic infiltration into the central nervous system. BNS is an extramedullary manifestation of WM which may present with various neurological signs and symptoms that make the diagnosis difficult to achieve. We present a case of BNS in a 60-year-old patient diagnosed 6 years after recovering from Waldenstrom’s macroglobulinemia. We observed the patient for a secondary generalized focal motor seizure. Unenhanced brain CT revealed slight hyperdensity of left parietal subarachnoid spaces. The MRI of the brain and spinal cord showed leptomeningeal enhancement in both parietal lobes. The presence of monoclonal bands (light chain k and IgM) was found in cerebrospinal fluid, leading to the diagnosis of BNS. The patient started treatment with ibrutinib and remains clinically stable during a 1-year follow-up. However, the MRI showed the appearance of a new subcortical left parietal lesion. BNS is an extremely rare presentation of WM that should be recognized and considered early in the presence of unexplained neurological symptoms in patients with a history of WM, even if the patient appears to have recovered. Full article
(This article belongs to the Special Issue Case Reports of Precision Medicine in Oncology)
Show Figures

Figure 1

Back to TopTop